These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32219722)

  • 21. Use of Direct Oral Anticoagulants in Patients with Sickle Cell Disease and Venous Thromboembolism: A Prospective Cohort Study of 12 Patients.
    Christen JR; Bertolino J; Jean E; Camoin L; Ebbo M; Harlé JR; Schleinitz N; Sarlon G; Bernit E
    Hemoglobin; 2019; 43(4-5):296-299. PubMed ID: 31724442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system.
    Villines TC; Ahmad A; Petrini M; Tang W; Evans A; Rush T; Thompson D; Oh K; Schwartzman E
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):80-90. PubMed ID: 30500885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM; Silva MA; Donovan JL; Kanaan AO
    Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hospital length of stay in patients initiated on direct oral anticoagulants versus warfarin for venous thromboembolism: a real-world single-center study.
    Badreldin H
    J Thromb Thrombolysis; 2018 Jul; 46(1):16-21. PubMed ID: 29626281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and safety of oral direct factor Xa inhibitors for the treatment of venous thromboembolism in patients with cancer and/or older age.
    Sato D; Ikeda S; Koga S; Yamagata Y; Eguchi M; Yonekura T; Tsuneto A; Yoshimuta T; Koide Y; Kawano H; Maemura K
    Heart Vessels; 2019 Apr; 34(4):678-687. PubMed ID: 30341629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
    Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
    Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.
    van Es N; Coppens M; Schulman S; Middeldorp S; Büller HR
    Blood; 2014 Sep; 124(12):1968-75. PubMed ID: 24963045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
    Perales IJ; San Agustin K; DeAngelo J; Campbell AM
    Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
    [No Abstract]   [Full Text] [Related]  

  • 29. Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease.
    Schafer JH; Casey AL; Dupre KA; Staubes BA
    Ann Pharmacother; 2018 Nov; 52(11):1078-1084. PubMed ID: 29871510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants.
    Testa S; Paoletti O; Legnani C; Dellanoce C; Antonucci E; Cosmi B; Pengo V; Poli D; Morandini R; Testa R; Tripodi A; Palareti G
    J Thromb Haemost; 2018 May; 16(5):842-848. PubMed ID: 29532628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study.
    Jun M; Lix LM; Durand M; Dahl M; Paterson JM; Dormuth CR; Ernst P; Yao S; Renoux C; Tamim H; Wu C; Mahmud SM; Hemmelgarn BR;
    BMJ; 2017 Oct; 359():j4323. PubMed ID: 29042362
    [No Abstract]   [Full Text] [Related]  

  • 32. Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses.
    Briasoulis A; Gao Y; Inampudi C; Alvarez P; Asleh R; Chrischilles E; Leira EC; Vaughan-Sarrazin M
    BMC Cardiovasc Disord; 2020 Feb; 20(1):42. PubMed ID: 32013886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial.
    Cohen AT; Agnelli G; Buller HR; Gallus A; Raskob GE; Sanders P; Thompson J; Weitz JI
    Thromb Haemost; 2019 Mar; 119(3):461-466. PubMed ID: 30650446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series.
    Beyer-Westendorf J; Michalski F; Tittl L; Hauswald-Dörschel S; Marten S
    Lancet Haematol; 2016 Oct; 3(10):e480-e488. PubMed ID: 27692306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the efficacy and safety of apixaban and rivaroxaban in cancer patients receiving concomitant active anti-neoplastic therapy at an outpatient cancer setting.
    Yassine D; Brown EN; Putney D; Fasoranti O
    J Oncol Pharm Pract; 2020 Oct; 26(7):1650-1656. PubMed ID: 32063102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism.
    Houghton DE; Vlazny DT; Casanegra AI; Brunton N; Froehling DA; Meverden RA; Hodge DO; Peterson LG; McBane RD; Wysokinski WE
    Mayo Clin Proc; 2021 Nov; 96(11):2793-2805. PubMed ID: 34425962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study.
    Hendriks T; McGregor S; Rakesh S; Robinson J; Ho KM; Baker R
    PLoS One; 2020; 15(6):e0234048. PubMed ID: 32497116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
    Cohen AT; Hamilton M; Bird A; Mitchell SA; Li S; Horblyuk R; Batson S
    PLoS One; 2016; 11(8):e0160064. PubMed ID: 27487187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
    Agnelli G; Buller HR; Cohen A; Gallus AS; Lee TC; Pak R; Raskob GE; Weitz JI; Yamabe T
    J Thromb Haemost; 2015 Dec; 13(12):2187-91. PubMed ID: 26407753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retrospective Evaluation of Postoperative Adverse Drug Events in Patients Receiving Rivaroxaban After Major Orthopedic Surgery Compared with Standard Therapy in a Community Hospital.
    Cieri NE; Kusmierski K; Lackie C; Van Opdorp A; Hassan AK
    Pharmacotherapy; 2017 Feb; 37(2):170-176. PubMed ID: 28028830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.